翰森制药口服 GLP-1R 激动剂启动肥胖 II 期临床

Insight数据库2025-05-07

5 月 6 日，翰森制药在药物临床试验登记与信息公示平台上登记了一项在超重和肥胖受试者中评估每天一次口服 HS-10501/HS-10501-2 的有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅱ 期临床研究。来源：药物临床试验登记与信息公示平台官网这是一项多中心、随机、双盲、安慰剂对照的 II 期临床研究，旨在超重伴有至少 1 种体重相关合并症和肥胖的成人受试者中评估每天一次口服 HS-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533630673?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-07 11:20","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533630673","market":"hk","top_or_hot":-1,"title":"翰森制药口服 GLP-1R 激动剂启动肥胖 II 期临床","media":"Insight数据库","content":"<div>\n<p>5 月 6 日，翰森制药在药物临床试验登记与信息公示平台上登记了一项在超重和肥胖受试者中评估每天一次口服 HS-10501/HS-10501-2 的有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅱ 期临床研究。来源：药物临床试验登记与信息公示平台官网这是一项多中心、随机、双盲、安慰剂对照的 II 期临床研究，旨在超重伴有至少 1 种体重相关合并症和肥胖的成人受试者中评估每天一次口服 HS-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰森制药口服 GLP-1R 激动剂启动肥胖 II 期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森制药口服 GLP-1R 激动剂启动肥胖 II 期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 11:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b><strong>Insight数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5 月 6 日，翰森制药在药物临床试验登记与信息公示平台上登记了一项在超重和肥胖受试者中评估每天一次口服 HS-10501/HS-10501-2 的有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅱ 期临床研究。来源：药物临床试验登记与信息公示平台官网这是一项多中心、随机、双盲、安慰剂对照的 II 期临床研究，旨在超重伴有至少 1 种体重相关合并症和肥胖的成人受试者中评估每天一次口服 HS-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b","article_id":"2533630673","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533630673","pubTimestamp":1746588036,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5 月 6 日，翰森制药在药物临床试验登记与信息公示平台上登记了一项在超重和肥胖受试者中评估每天一次口服 HS-10501/HS-10501-2 的有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅱ 期临床研究。该研究计划纳入 540 名受试者，随机分组接受HS-10501、HS-10501-2、安慰剂治疗，每日一次。HS-10501 用药时程为 36 周，HS-10501-2 用药时程为 26 周。主要终点是给药 26 周后，体重较基线下降的百分比。HS-10501-2 剂型为缓释片。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1589":"北水核心资产","03692":"翰森制药","BK1191":"制药"},"translate_title":"Hansoh Pharmaceutical's oral GLP-1R agonist initiates phase II clinical trial for obesity","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"5 月 6 日，翰森制药在药物临床试验登记与信息公示平台上登记了一项在超重和肥胖受试者中评估每天一次口服 HS-10501/HS-10501-2 的有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅱ 期临床研究。来源：药物临床试验登记与信息公示平台官网这是一项多中心、随机、双盲、安慰剂对照的 II 期临床研究，旨在超重伴有至少 1 种体重相关合并症和肥胖的成人受试者中评估每天一次口服 HS-10501 和 HS-10501-2 的有效性和安全性。该研究计划纳入 540 名受试者，随机分组接受HS-10501（5mg、20mg）、HS-10501-2（5mg、10mg）、安慰剂治疗，每日一次。HS-10501 用药时程为 36 周，HS-10501-2 用药时程为 26 周。主要终点是给药 26 周后，体重较基线下降的百分比。次要终点包括体重较基线下降的百分比、体重较基线变化的绝对值、体重较基线下降 ≥ 5% 的受试者比例、体重较基线下降 ≥ 10% 的受试者比例、BMI较基线的变化、腰围较基线的变化、收缩压较基线的变化、总胆固醇（TC）等。来源：药物临床试验登记与信息公示平台官网HS-10501 是一款GLP-1R 激动剂，剂型为普通片剂。HS-10501-2 剂型为缓释片。封面来源：企业logo","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533630673","isCrawlerRequest":true}